She is also on the Board of Directors at Pluristem Therapeutics. Some of her other previous positions include Director of Strategic and Product Marketing at Oracle Healthcare and Precision Medicine, Vice President of Global Marketing at JPMorgan Chase Bank, and Founder and CEO of Rasmussen Communications. In this role, she defined Roche’s new health tech strategy, bringing to market advanced digital solutions and commercial models that positioned Roche as a world leader in health technology.
Maital comes to Octave Bioscience from Roche (DIS), where she served as Global Head of Solution Marketing. Maital is a leader in global digital health marketing strategy with extensive experience in the growth and commercialization of patient-centric, data-driven personalized care products and value-based approaches. He also holds a Master of Science in Mechanical Engineering (Diplome d’Ingenieur) from Sup’Meca, Saint-Ouen, France. Erwan holds a Global Executive MBA from TRIUM, a joint degree between NYU Stern, London School of Economics and HEC Paris. He led a firewall release with projected revenues of $1.5B, delivered on time and within budget. Erwan credits his time at Cisco as being the most formative for developing his leadership, strategic and program skills. Prior to that, he led teams at high tech start-ups, Cisco and Logitech. Prior to this, he led a 300 engineers research and development team for building control systems at Honeywell, developing global digital IoT platforms for home automation and commercial buildings.
Octave bioscience software#
Prior to Octave Bioscience, he was global head of software engineering for the medical device group at EMD Serono, in Switzerland, integrating health in people’s digital life for the chronic diseases, growth hormones, and consumer divisions. Bill holds a BS in Business Management from Bob Jones University.Įrwan has over two decades experience in both start-ups and global corporations across multiple industries: high tech, industrials, and digital health. Previously he was on the board of Prometheus Laboratories. He currently serves on the board of directors for CareDx, Navican, Genalyte and CoFactor. Earlier in his career, he was Vice President of Baxter International’s $1.0 billion Scientific Products Division and held management positions at the American Hospital Supply and Becton Dickinson. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company which he scaled from start-up through IPO. Prior to that, he served as the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. While at Alpha BioPartners, Bill created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals. Prior to this, he was the President of Alpha BioPartners, a strategic consulting firm advising the launch of new life sciences companies. Prior to founding Octave Bioscience, he served as the CEO of Crescendo Bioscience which created novel measurement tools and software in the field of rheumatology. Bill has more than 25 years of start-up experience in a broad range of medical specialties intersecting science, technology, clinical medicine, and business strategy.
0 kommentar(er)
